Article

AlphaMissense pathogenicity scores predict response to immunotherapy and enhances the predictive capability of tumor mutation burden

2025-10-01

Abstract excerpt

Tumor Mutational Burden (TMB) is a widely used biomarker for selecting cancer patients for immune checkpoint inhibitor (ICI) therapy. However, TMB alone has limited predictive power, as it fails to account for the functional impact of mutations. We introduce AlphaTMB, a composite biomarker that integrates the quantity of mutations (TMB) with the qualitative assessment of their pathogenicity using AlphaMissense, a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2cd5cfd7-8294-5c27-8612-27744a381084
DOI: 10.1101/2025.09.28.679078

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

AlphaMissense pathogenicity scores predict response to immunotherapy and enhances the predictive capability of tumor mutation burdenDOI 10.1101/2025.09.28.679078Read

Novel tumor mutation score versus tumor mutation burden in predicting survival after immunotherapy in pan-cancer patients from the MSK-IMPACT cohortSemantic proximity Read

Is tumor mutational burden predictive of response to immunotherapy?Semantic proximity Read

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival.Semantic proximity Read

Prediction of immunotherapy response using mutations to cancer protein assemblies.Semantic proximity Read

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current EvidenceSemantic proximity Read

APOBEC3G expression marks a TMB-high, T cell-inflamed tumor state and is associated with response to immune checkpoint blockade in multiple cancer cohortsSemantic proximity Read

A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid TumoursSemantic proximity Read

A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid Tumours.Semantic proximity Read

TMBserval: a statistical explainable learning model reveals weighted tumor mutation burden better categorizing therapeutic benefits.Semantic proximity Read

MARiO: predicting cancer variant pathogenicity by integrating <i>in silico</i> evaluation and patient-level mutational contextsSemantic proximity Read

Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkersSemantic proximity Read

Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy.Semantic proximity Read